THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/ --
Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)